PPARA and metabolic disease: In vitro, FGF15/19 intervention attenuated PA‐induced metabolic disorders and lipid accumulation in mouse atrial cardiomyocytes coupled with increased inflammation and the phosphorylation of CaMKII and YAP, which was reversed by the PPARα inhibitor.